112 subjects. Zero reactions. Here's the full study.
We tested mivida Vitamin E Makeup Remover Wipes on 112 people at an independent US laboratory — including 56 with self-perceived sensitive skin. Here's the methodology, the results, and what the study doesn't tell you.
We test our formulas on people, at independent laboratories, before we sell them. Then we publish what the testing found — including what it doesn't tell you.
This page documents the skin irritation and sensitization study for mivida Vitamin E Makeup Remover Wipes.
What a Human Repeat Insult Patch Test is
A Human Repeat Insult Patch Test is the standard method the cosmetics industry uses to evaluate whether a finished product can cause skin irritation or trigger contact sensitization — an allergic response that develops after repeated exposure.
It works in two phases. During the induction phase, the product is applied repeatedly to the same site on the skin under an occlusive patch, which holds the product against the skin far more aggressively than normal use. Then, after a rest period, a challenge patch is applied to a site that has not been exposed before. Irritation shows up during induction; sensitization shows up at challenge.
The exaggerated, occluded exposure is the point. If a formula is going to react, this is the method designed to find it.
Who was tested
120 adults were enrolled and 112 completed the full study.
Age: 19 to 70 years
Self-perceived sensitive skin: 56 of the 112 who completed — half the panel
Fitzpatrick skin types: I through VI, all six represented
Backgrounds: African American, Asian, Caucasian, Hispanic/Latino, Indian, and other
Sex: 87 female, 25 male
Eight enrolled subjects did not complete the study. All eight were recorded as lost to follow-up. None discontinued because of a skin reaction.
A note on "sensitive skin": these subjects identified themselves as having sensitive skin during screening. They were not clinically diagnosed. We say this plainly because the difference matters, and because most brands don't.
How it was tested
The study was conducted at Eurofins | CRL, Inc., an independent clinical testing laboratory in Piscataway, New Jersey, under the supervision of a Principal Investigator who is a board-certified dermatologist (Diplomate, American Board of Dermatology). It followed the laboratory's standard operating procedures and applicable ICH GCP standards, and was reviewed by the laboratory's quality assurance function.
The product was tested as received — the finished wipe, not a diluted sample or an isolated ingredient.
Nine induction applications were made under occlusive patches, followed by a challenge phase with evaluations at 24, 48 and 72 hours.
Every evaluation was scored on a standard dermal scale running from 0 (no visible skin reaction) through 4+ (erythema and edema with vesiculation), alongside coded observations for effects such as edema, dryness, peeling, itching and burning.
What the study found
Every subject who completed the study scored 0 at every evaluation, through both the induction and challenge phases.
No protocol deviations occurred during the study.
Based on the test population of 112 subjects, 56 of whom had self-perceived sensitive skin, and under the conditions of this study, mivida Vitamin E Makeup Remover Wipes did not demonstrate a potential for eliciting dermal irritation or inducing sensitization.
What this study does not tell you
An HRIPT answers one question: does repeated, occluded exposure to this product cause skin irritation or sensitization in the people tested? It is a thorough answer to that question and not an answer to any other.
This study does not establish that the product:
• removes makeup effectively, cleanses, hydrates, or moisturises — no efficacy testing was performed
• improves the skin barrier, reduces redness, or calms inflammation
• is non-comedogenic or suitable for acne-prone skin — that requires a separate study
• is suitable for use around the eyes — no ocular safety testing was performed
• is appropriate for anyone with a diagnosed skin condition such as rosacea, eczema, or dermatitis
• is suitable for children, or for use during pregnancy — the youngest subject was 19
• is safe over years of use — this study ran approximately six weeks
It also cannot establish that no person will ever react to this product. No cosmetic study can. A panel of 112 people is a strong signal, not a guarantee, and anyone with a known sensitivity should patch test first and consult their doctor.
Study number ECRLNJ2025-1054. Conducted by Eurofins | CRL, Inc., 371 Hoes Lane, Suite 100, Piscataway, New Jersey. Report finalised 25 February 2026.
The full clinical study report is available on request to retail, marketplace, and regulatory partners. Contact [info@mividaskincare.com].